A drug compound attacks hard-to-treat prostate cancer on several fronts, according to a Washington University School of Medicine in St. Louis study in mice and human cells. It triggers immune cells to attack, helps the immune cells penetrate the tumor and cuts off the tumor’s ability to burn testosterone as fuel.